Clinical Trials List
2019-05-01 - 2027-12-31
Phase III
Terminated5
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Jyh-Pyng Gau Division of Hematology & Oncology
- Sheng-Hsuan Chien Division of Hematology & Oncology
- Po-Shen Ko Division of Hematology & Oncology
- Ting-An Lin 無
- Yao-Chung Liu 無
- Hao-Yuan Wang Division of Hematology & Oncology
- Chia-Jen Liu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Ming-Chung Kao Division of Hematology & Oncology
- Tung-Liang Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 田豐銘 Division of General Internal Medicine
- HSIN-AN HOU Division of General Internal Medicine
- Tai-Chung Huang Division of General Internal Medicine
- Chieh-Lung Cheng Division of General Internal Medicine
- Chien-Chin Lin Division of General Internal Medicine
- Jih-Luh Tang Division of General Internal Medicine
- CHENG-HONG TSAI Division of General Internal Medicine
- 林建廷 Division of General Internal Medicine
- - - Division of General Internal Medicine
- 劉家豪 Division of General Internal Medicine
- MING YAO Division of General Internal Medicine
- Huai-Hsuan Huang Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Ming-Yu Lien Division of Hematology & Oncology
- Ming-Hung Tsai Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
- Chen-Yuan Lin Division of Hematology & Oncology
- Tzu-Ting Chen Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- Ching Yun Hsieh Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
19 participants
-
Global
1115 participants